You are here

Article Text

Article menu

Download PDFPDF

News and notes
News and updates from palliativedrugs.com
  1. Andrew Wilcock1 and
  2. Sarah Charlesworth2
  1. 1Department of Palliative Medicine, University of Nottingham, Nottingham, UK
  2. 2Hayward House Study Centre, palliativedrugs.com, Nottingham, UK
  1. Correspondence to Dr Andrew Wilcock, Department of Palliative Medicine, University of Nottingham, Nottingham NG5 1PB, UK; andrew.wilcock{at}nottingham.ac.uk

https://doi.org/10.1136/bmjspcare-2014-000755

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The website http://www.palliativedrugs.com has provided essential independent information about drugs used in palliative and hospice care for over a decade. It contains the online Palliative Care Formulary (PCF) and provides free access to a Bulletin Board to stimulate questions and share experiences, a document library containing 475 items of useful information and a Syringe Driver Survey Database containing details of over 2350 different drug combinations. Territory-specific book versions (the UK Palliative Care Formulary, Hospice and Palliative Care Formulary USA 2nd edition and Palliative Care Formulary Canadian edition) and an ebook PDF version of the PCF can also be purchased via the website. This feature provides a selection of items that have been featured in the News and Latest Additions sections in recent months; for additional information, please register for free on the website.

    Safety updates

    Domperidone restrictions

    The European Medicines Agency (EMA) has recommended changes to the indications, dose and duration of use of domperidone in adults and children following a review. This follows concerns highlighted in 2012 that domperidone is associated with a small increased risk of serious cardiac undesirable effects. Domperidone is now:

    • Indicated for nausea and vomiting only, all other uses are unauthorised.

    • Contraindicated in patients:

      • Where cardiac conduction is, or could be, impaired;

      • With underlying cardiac disease, for example, chronic heart failure;

      • With severe hepatic impairment;

      • Concurrently receiving drugs known to be CYP3A4 inhibitors and/or cause QT prolongation.

    In addition, domperidone:

    • Should be used at the …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.